Risk factors for radiation-induced lung injury in patients with advanced non-small cell lung cancer: implication for treatment strategies

被引:4
作者
Sha, Sha [1 ]
Dong, Jigang [1 ]
Wang, Maoyu [1 ]
Chen, Ziyu [1 ]
Gao, Peng [1 ]
机构
[1] Jiaozhou Cent Hosp, Dept Radiotherapy, 29 Xuzhou Rd, Qingdao 266300, Peoples R China
关键词
Radiation; Lung injury; Non-small cell lung cancer; Treatment; Care; RETROSPECTIVE ANALYSIS; TOXICITY PREDICTORS; THERAPY; RADIOTHERAPY; PNEUMONITIS; APPEARANCE; RECURRENCE; DIAGNOSIS;
D O I
10.1186/s12957-021-02321-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The radiation-induced lung injury (RILI) in patients with advanced non-small cell lung cancer (NSCLS) is very common in clinical settings; we aimed to evaluate the risk factors of RILI in NSCLS patients, to provide insights into the treatment of NSCLS. Methods: NSCLC patients undergoing three-dimensional conformal radiotherapy (3D-CRT) in our hospital from June 1, 2018, to June 30, 2020, were included. The characteristics and treatments of RILI and non-RILI patients were analyzed. Logistic regression analyses were conducted to assess the risk factors of RILI in patients with NSCLC. Results: A total of 126 NSCLC patients were included; the incidence of RILI in NSCLC patients was 35.71%. There were significant differences in diabetes, smoke, chronic obstructive pulmonary disease (COPD), concurrent chemotherapy, radiotherapy dose, and planning target volume (PTV) between the RILI group and the non-RILI group (all P < 0.05). Logistic regression analyses indicated that diabetes (OR 3.076, 95%CI 1.442 similar to 5.304), smoke (OR 2.745, 95%CI 1.288 similar to 4.613), COPD (OR 3.949, 95%CI 1.067 similar to 5.733), concurrent chemotherapy (OR 2.072, 95%CI 1.121 similar to 3.498), radiotherapy dose >= 60 Gy (OR 3.841, 95%CI 1.932 similar to 5.362), and PTV >= 396 (OR 1.247, 95%CI 1.107 similar to 1.746) were the independent risk factors of RILI in patients with NSCLC (all P < 0.05). Conclusions: RILI is commonly seen in NSCLS patients; early targeted measures are warranted for patients with those risk factors; future studies with larger sample sizes and different areas are needed to further elucidate the influencing factors of RILI in the treatment of NSCLS.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
    Zhai, Xiaoyang
    Zhang, Jian
    Tian, Yaru
    Li, Ji
    Jing, Wang
    Guo, Hongbo
    Zhu, Hui
    CANCER BIOLOGY & MEDICINE, 2020, 17 (03) : 599 - 611
  • [22] Treatment Toxicity in Elderly Patients With Advanced Non-Small Cell Lung Cancer
    Kale, Minal S.
    Mhango, Grace
    Gomez, Jorge E.
    Sigel, Keith
    Smith, Cardinale B.
    Bonomi, Marcelo
    Wisnivesky, Juan P.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (05): : 470 - 476
  • [23] Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation
    Martins, RG
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 26 (03) : 273 - 277
  • [24] Personalized treatment of advanced non-small cell lung cancer
    Koehler, J.
    Schuler, M.
    ONKOLOGE, 2011, 17 (08): : 702 - +
  • [25] Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer
    Zhao, Jing
    Day, Regina M.
    Jin, Jian-Yue
    Quint, Leslie
    Williams, Hadyn
    Ferguson, Catherine
    Yan, Li
    King, Maurice
    Albsheer, Ahmad
    Matuszak, Martha
    Kong, Feng-Ming
    ONCOTARGET, 2017, 8 (57) : 97623 - 97632
  • [26] Investigating the SPECT Dose-Function Metrics Associated With Radiation-Induced Lung Toxicity Risk in Patients With Non-small Cell Lung Cancer Undergoing Radiation Therapy
    Owen, Daniel R.
    Sun, Yilun
    Boonstra, Philip S.
    McFarlane, Matthew
    Viglianti, Benjamin L.
    Balter, James M.
    El Naqa, Issam
    Schipper, Matthew J.
    Schonewolf, Caitlin A.
    Ten Haken, Randall K.
    Kong, Feng-Ming S.
    Jolly, Shruti
    Matuszak, Martha M.
    ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (03)
  • [27] Treatment of advanced non-small cell lung cancer
    De Petris, L
    Crinò, L
    Scagliotti, GV
    Gridelli, C
    Galetta, D
    Metro, G
    Novello, S
    Maione, P
    Colucci, G
    de Marinis, F
    ANNALS OF ONCOLOGY, 2006, 17 : 36 - 41
  • [28] CRIZOTINIB FOR THE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A. J.
    Doebele, R. C.
    Camidge, D. R.
    Jimeno, A.
    DRUGS OF TODAY, 2012, 48 (04) : 271 - 282
  • [29] PREDICTIVE FACTORS OF LATE RADIATION FIBROSIS: A PROSPECTIVE STUDY IN NON-SMALL CELL LUNG CANCER
    Mazeron, Renaud
    Etienne-Mastroianni, Benedicte
    Perol, David
    Arpin, Dominique
    Vincent, Michel
    Falchero, Lionel
    Martel-Lafay, Isabelle
    Carrie, Christian
    Claude, Line
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (01): : 38 - 43
  • [30] Prognostic factors in older patients with advanced non-small cell lung cancer in China
    Su, Qiang
    Sun, Yu-Ping
    Liu, Ye-Hui
    Li, Zhe
    Yang, Hong-Yan
    Sun, Zhi-Gang
    Cao, Bang-Wei
    Jia, Ji-Hui
    TUMORI, 2014, 100 (01) : 69 - 74